EcoDrugPlus

Protein Kinase C Zeta Type

Ensembl ID : ENSPNAG00000001667
Gene Symbol: LOC108415593
3 Cross references
201 Possible Orthologues:

Protein Kinase D1

Ensembl ID : ENSPNAG00000019084
Gene Symbol: PRKD1
3 Cross references
204 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSPNAG00000010771
Gene Symbol: PRKD3
4 Cross references
201 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSPNAG00000015710
Gene Symbol: PRKD3
3 Cross references
209 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSPNAG00000020574
Gene Symbol: PRKDC
3 Cross references
184 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSPNAG00000016996
Gene Symbol: PPP3CA
4 Cross references
234 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSPNAG00000017725
Gene Symbol: PTK2
3 Cross references
193 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSPNAG00000000264
Gene Symbol: PTK2B
3 Cross references
200 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSPNAG00000002463
Gene Symbol: PTPN11
3 Cross references
251 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSPNAG00000017731
Gene Symbol: PTPRB
3 Cross references
203 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSPNAG00000021608
Gene Symbol: PTPRB
3 Cross references
189 Possible Orthologues:

Protein-Serine O-Palmitoleoyltransferase Porcupine-Like

Ensembl ID : ENSPNAG00000027056
Gene Symbol: LOC108441640
3 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).